A Phase 1/2 Single-arm Clinical Trial of Recombinant Bacillus Calmette-Guérin (BCG) VPM1002BC Immunotherapy in Non–muscle-invasive Bladder Cancer Recurrence After Conventional BCG Therapy: SAKK 06/14

Cyrill A. Rentsch,George N. Thalmann,Ilaria Lucca,Maciej Kwiatkowski,Grégory J. Wirth,Räto T. Strebel,Daniel Engeler,Augusto Pedrazzini, Clemens Hüttenbrink, Wolfgang Schultze-Seemann, Raimund Torpai,Lukas Bubendorf,Andreas Wicki,Beat Roth,Piet Bosshard,Heike Püschel,Daniel T. Boll, Lukas Hefermehl,Florian Roghmann,Michael Gierth

European Urology Oncology（2022）

引用 10|浏览11

暂无评分

摘要

Intravesical therapy with the recombinant bacillus Calmette-Guérin (BCG) strain VPM1102BC is safe and well tolerated and maintains quality of life in 70% of patients. Of patients who had received previous standard BCG induction with or without BCG maintenance therapy, more than 49% and 43% remained without recurrence after 1 and 3 yr, respectively.

查看译文

关键词

Bacillus Calmette-Guérin,Genomically modified organism,Non–muscle-invasive bladder cancer,Phase 2 single-arm trial,VPM1002BC

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要